Title The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol
Authors Lv, Xiaozhen
Si, Tianmei
Wang, Gang
Wang, Huali
Liu, Qi
Hu, Changqing
Wang, Jing
Su, Yunai
Huang, Yu
Jiang, Hui
Yu, Xin
Affiliation Peking Univ Sixth Hosp, Inst Mental Hlth, Beijing, Peoples R China.
Peking Univ, Minist Hlth, Natl Clin Res Ctr Mental Disorders, Beijing, Peoples R China.
Peking Univ, Minist Hlth, Key Lab Mental Hlth, Beijing, Peoples R China.
Capital Med Univ, Beijing Anding Hosp, Beijing, Peoples R China.
Peking Univ, Natl Engn Res Ctr Software Engn, Beijing, Peoples R China.
Peking Univ Sixth Hosp, Inst Mental Hlth, Beijing, Peoples R China.
Yu, X (reprint author), Peking Univ, Minist Hlth, Natl Clin Res Ctr Mental Disorders, Beijing, Peoples R China.
Yu, X (reprint author), Peking Univ, Minist Hlth, Key Lab Mental Hlth, Beijing, Peoples R China.
Keywords Major depressive disorder
Subtype
Diagnostic
Personalized treatment
ANTIDEPRESSANT TREATMENT
CLINICAL CHARACTERISTICS
TREATMENT RESPONSE
MOOD DISORDERS
METAANALYSIS
BIOMARKERS
OUTCOMES
ASSOCIATION
INPATIENTS
BURDEN
Issue Date 2016
Publisher BMC PSYCHIATRY
Citation BMC PSYCHIATRY.2016,16.
Abstract Background: Major depressive disorders (MDD) is a common mental disorder with high prevalence, frequent relapse and associated with heavy disease burden. Heritability, environment and their interaction play important roles in the development of MDD. MDD patients usually display a wide variation in clinical symptoms and signs, while the diagnosis of MDD is relatively subjective. The treatment response varies substantially between different subtypes of MDD patients and only half respond adequately to the first antidepressant. This study aims to define subtypes of MDD, develop multi-dimension diagnostic test and combined predictors for improving the diagnostic accuracy and promoting personalized intervention in MDD patients. Methods/Design: This is a multi-center, multi-stage and prospective study. The first stage of this study is a case-control study, aims to explore the risk factors for developing MDD and then define the subtypes of MDD using 1200 MDD patients and 1200 healthy controls with a set of questionnaire. The second stage is a diagnostic test, aims to indentify and replicate the potential indicators to assist MDD diagnosis using 600 MDD patients and 300 healthy controls from the first stage with a set of questionnaire, neuropsychological assessment and a series of biomarkers. The third stage is a 96-week longitudinal study, including 8-week acute period treatment and 88-week stable period treatment, aims to identify overall predictors of treatment effectiveness on MDD at week 8 post treatment and to explore the predictors on MDD prognosis in the following 2 years using 600 MDD patients from the first stage with a set of questionnaire, neuropsychological assessment and a series of biomarkers. The primary outcome measure is the change of the total score of 17-Item Hamilton Rating Scale for Depression. Discussion: This study will provide strong and suitable evidence for enhancing the accuracy of MDD diagnosis and promoting personalized treatment for MDD patients in clinical practice.
URI http://hdl.handle.net/20.500.11897/491879
ISSN 1471-244X
DOI 10.1186/s12888-016-0953-z
Indexed SCI(E)
PubMed
Appears in Collections: 第六医院

Files in This Work
There are no files associated with this item.

Web of Science®


0

Checked on Last Week

Scopus®



Checked on Current Time

百度学术™


0

Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.